Owlstone Medical Opens High-Volume Breath Biopsy Lab
Facilities will have access to high-throughput biomarker services for identification of novel breath biomarkers in disease diagnostics and precision medicine applications.
Read More
Search Results for: lung cancer
Multiplex cfDNA Reference Standard Set in Synthetic Plasma
The new format directly addresses DNA extraction, one of the key sources of variability in cfDNA assays.
Read More
The Evolution of the PD-L1 Testing Market
The dynamic PD-L1 space is providing opportunities to undertake real-time market analysis and ultimately improve our understanding of novel biomarker adoption.
Read More
ROS1, RET Now Available in Liquid Biopsy Test
The test provides highly sensitive results in 72 hours for non-small cell lung cancer patients.
Read More
Company to Commercialize Proteomic Blood Test in China
The partners will also collaborate on the development of new mass spectrometry-based assays in oncology and other clinical areas.
Read More